A new dosing platform for the whole world:
The right patient
The right drug
The right time
The right dose
The right route

New approaches to drug dosing and consumption are resulting from a better understanding of the molecular mechanisms of the human body and have rapidly developed in recent decades. A population-based approach of “one tablet, three times a day” is becoming a thing of the past. New knowledge about the effects of active substances opens up new pharmacokinetic possibilities for the handling of medicines.

The technology of the Right5 platform is based on Bayesian statistical and Therapeutic Drug Monitoring (TDM) pharmacology methods.

We have developed Right5, a core software based on Bayesian statistics configured to optimize vancomycin treatment doses in neonates. We have tested the ability of the software to adjust the dose retrospectively in a pooled database (in silico) and have shown that dose adjustment by the Bayesian method could significantly improve the achievement of the therapeutic goal of vancomycin.

We have also discovered the effect of different a priori inputs (existing pharmacokinetic models) on the predictive power of dose optimization software. We have tested various neonatal vancomycin pharmacokinetic models published in the literature in silico and have shown that the choice of input model significantly affects the accuracy of software dose optimization. We have also shown that the Bayesian method (on which the software is based on) significantly reduces the systematic error of the models.